The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Salvage chemotherapy versus best supportive care in patients with recurrent or metastatic squamous cell carcinoma of the esophagus refractory or intolerable to fluorouracil, platinum, and taxane.
 
Takahiro Tsushima
Honoraria - Eisai; Taiho Pharmaceutical; Takeda
 
Motoo Nomura
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Satoru Iwasa
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Ken Kato
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Dainippon Sumitomo Pharma; Lilly; Nippon Kayaku; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Hirofumi Yasui
No Relationships to Disclose
 
Kei Muro
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
 
Narikazu Boku
Honoraria - Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Shionogi
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)